arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

CytoDyn Inc.

CYDY
Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
55
Health
Fair
Bullish
auto_awesome

Analytical Summary

CytoDyn Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap
Dividend Yield
Revenue Growth
Op. Margin
ROIC -19.1%
FCF / Share $-0.01
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.47
info Valuation on last close.

23-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$266.00K
Net Income Profit after all expenses
$3.75M
↑ +107.5%
FCF / Share Free cash flow per share
$-0.01
↑ +35.8%
Long-Term Debt Long-term obligations
$45.35M
↑ +0.7%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
39
Financial Health
99
Cash Quality
6

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 23 years · 70 quarters